Amazing Keytruda Case Study Offers Hope for Advanced Mesothelioma
| | |

Amazing Keytruda Case Study Offers Hope for Advanced Mesothelioma

ByAlex Strauss

Italian doctors are reporting an “impressive clinical response” in a recently published Keytruda case study. The case is encouraging news for people with advanced malignant mesothelioma.   The case involves a 45-year-old woman with metastatic pleural mesothelioma. Doctors found cancer in her chest, brain, and abdomen. Even after several kinds of chemotherapy, the patient continued to go down hill.  Finally, when it looked like the woman would not live much longer, doctors tried Keytruda (pembrolizumab). The Keytruda case study documents the patient’s amazing turnaround.  Case Looked Hopeless The 45-year old woman in the Keytruda case study first went to the doctor because of shortness of breath. Doctors found that she had pleural effusion. This is a build-up of lung fluid that…

Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results
| | | | |

Pembrolizumab for Mesothelioma Dealt Setback by New Trial Results

ByAlex Strauss

There has been a setback for researchers focused on the promise of pembrolizumab for mesothelioma. New research suggests that pembrolizumab (Keytruda) may not be the miracle mesothelioma drug that some were hoping for.  The Phase III trial results were presented at a the European Society of Medical Oncology conference now underway in Spain. They suggest that pembrolizumab for mesothelioma may be no better than chemotherapy for improving survival. Pembrolizumab for Mesothelioma: How it Works Malignant pleural mesothelioma is a rare but lethal cancer. It is usually associated with on-the-job asbestos exposure. There is no cure. The only drug approved for mesothelioma treatment is Alimta (pemetrexed).   Cancer researchers around the world are working hard to find other mesothelioma treatments. Pembrolizumab for…

First-Line Keytruda Treatment May Support Longer Mesothelioma Survival
| | | |

First-Line Keytruda Treatment May Support Longer Mesothelioma Survival

ByAlex Strauss

New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona.  The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer.  Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line…